Women with hard-to-treat ovarian cancer will now have access to a new life-prolonging treatment after NHS England approved the use of mirvetuximab soravtansine, a targeted therapy designed for patients whose ovarian cancer has stopped responding to platinum-based chemotherapy.
Ovarian cancer starts in the ovaries, the organs in the female reproductive system that produce eggs and hormones. It is often called a “silent” cancer because early symptoms are vague and easily mistaken for other common conditions, often leading to delayed diagnosis.
The newly approved drug is intended for patients with platinum-resistant epithelial ovarian cancer, as well as cancers of the fallopian tube and peritoneum.
Unlike traditional chemotherapy, which attacks both cancerous and healthy cells, mirvetuximab soravtansine is designed to deliver treatment directly to cancer cells. It combines an antibody that targets cells carrying the FRα protein with a potent anti-cancer agent, allowing for more precise treatment.
According to the World Health Organisation, risk factors for ovarian cancer include increasing age, especially after menopause, a family history of ovarian or breast cancer, and inherited gene mutations such as BRCA1 and BRCA2.
Other factors linked to higher risk include endometriosis, never having been pregnant, a personal history of breast cancer, and use of hormone replacement therapy after menopause.
Early symptoms may include persistent bloating, pelvic or abdominal pain, feeling full quickly when eating, frequent urination, constipation, fatigue, and unexplained weight loss. Because these symptoms are non-specific, they are often overlooked.
The disease is difficult to treat mainly because it is usually diagnosed late, after it has already spread.
While many patients initially respond to surgery and chemotherapy, about 80 per cent of advanced cases relapse and may become resistant to treatment. It also spreads within the abdominal cavity, making complete removal difficult, and there is no reliable screening test for early detection.
Ovarian cancer remains one of the deadliest cancers affecting women globally. It is the 18th most common cancer worldwide and affects more than 300,000 women each year.
More than three-quarters of patients are diagnosed only after the disease has already spread beyond the ovaries, making treatment more challenging.
Current treatment usually involves surgery to remove as much of the tumour as possible, followed by chemotherapy.
While many patients initially respond well, about 80 per cent of women with advanced ovarian cancer experience a relapse, and many eventually develop resistance to chemotherapy, leaving limited treatment options.
Researchers say the targeted nature of mirvetuximab soravtansine may explain why patients experience fewer severe side effects compared with conventional chemotherapy. This could translate into better quality of life, fewer hospital visits for complications, and improved ability to maintain daily activities.
The approval follows encouraging results from an international clinical trial involving patients from several countries, including those treated in NHS hospitals. The study compared mirvetuximab soravtansine with standard chemotherapy in women with platinum-resistant ovarian cancer.
Results showed that the new treatment delayed disease progression and extended survival by an average of four months compared with chemotherapy alone. While modest, cancer specialists say this improvement is clinically significant in advanced ovarian cancer, especially when combined with better quality of life.
“The trial also found that more than one-third of patients receiving the drug experienced substantial tumour shrinkage.”
Researchers reported that about 37 per cent of patients saw tumour size reduced by at least 30 per cent, compared with 16 per cent in the chemotherapy group. These results suggest meaningful benefits for a significant proportion of patients with limited treatment options.
For many years, women with platinum-resistant ovarian cancer have had few effective options once chemotherapy stops working. The availability of a new targeted therapy offers renewed hope for patients and families facing an uncertain prognosis.
Experts also point to the psychological impact of treatment resistance in ovarian cancer, where being told chemotherapy is no longer effective can be devastating. The arrival of a new therapy provides reassurance that more options are emerging through advances in cancer research.
The approval reflects a broader shift in oncology toward precision medicine, where treatments are tailored to the biological characteristics of a patient’s cancer. By targeting specific proteins and genetic markers, researchers aim to develop therapies that are both more effective and less toxic.
While mirvetuximab soravtansine is not a cure, specialists say it represents a significant step forward in managing advanced ovarian cancer.
Its approval marks the first major new treatment option for this group of patients in more than two decades and highlights the growing role of targeted therapies in cancer care.
For women living with platinum-resistant ovarian cancer, the new treatment offers something often in short supply: more time, more options, and renewed hope in the fight against one of the most challenging forms of the disease.
Comments
Sign in with Google to comment, reply, and like comments.
Continue with Google